Physician profile
Tina Rutar
NPI 1861525248
$930.52
in general payments reported to CMS, 2019-2025
18 companies · $255 in 2025
The $255 reported for 2025 was more than what 76% of Pediatric Ophthalmology and Strabismus Specialist providers received nationally (typical 2025 total: $118).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $138 · 2021: $43.16 · 2022: $87.14 · 2023: $202 · 2024: $102 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $558.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Springworks Therapeutics, INC. | $125.00 | 2025 | Gomekli |
| Biotissue Holdings INC. | $121.26 | 2019-2020 | |
| Alcon Vision LLC | $107.24 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $92.33 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Johnson & Johnson Surgical Vision, INC. | $91.60 | 2023 | Tecnis Simplicity, Tecnis Iol |
| Dompe US, INC. | $62.07 | 2025 | Oxervate |
| Immunocore Limited | $53.61 | 2023 | Kimmtrak |
| Horizon Therapeutics Plc | $40.66 | 2021-2023 | Tepezza |
| Amgen INC. | $38.58 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $37.71 | 2024-2025 | Xdemvy |
| Abbvie INC. | $26.09 | 2024 | |
| Sun Pharmaceutical Industries INC. | $22.04 | 2022 | |
| Aerie Pharmaceuticals, INC. | $21.99 | 2019 | |
| Oyster Point Pharma, INC. | $20.05 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $18.51 | 2019 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| New World Medical,INC. | $15.14 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tina Rutar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.